# Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer

> **NCT07166185** · — · RECRUITING · sponsor: **Blida 1 University** · enrollment: 70 (estimated)

## Conditions studied

- Non Metastatic HER2 Positive Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07166185
- **Lead sponsor:** Blida 1 University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2025-10
- **Final completion:** 2025-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07166185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07166185, "Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07166185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*